SCHEMBL20047641

SCHEMBL20047641

Cc1cc(F)c2nc(C(C)C)ccc2c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
CCR1 P32246 2/20 0.38
CCR5 P51681 2/20 0.38
CCR8 P51685 2/20 0.38
CYP2A6 P11509 3/20 0.35
CYP1A2 P05177 2/20 0.35
PDE2A O00408 1/20 0.33
PDE10A Q9Y233 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
PSMD14 O00487 2/20 0.32
COPS5 Q92905 2/20 0.32
IDH1 O75874 1/20 0.32
HTR1B P28222 1/20 0.31
HTR2B P41595 1/20 0.31
GPR65 Q8IYL9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21161090 0.78 ALOX5AP (0.33)
SCHEMBL24619705 0.77 CCR1 (0.43) CCR1CCR5CCR8CYP2A6CYP1A2
SCHEMBL24482811 0.77 CCR1 (0.50) CCR1CCR5CCR8CYP2A6CYP1A2
SCHEMBL24619702 0.74 CCR1 (0.41) CCR1CCR5CCR8CYP2A6CYP1A2
SCHEMBL22509683 0.74 BACE1 (0.48) NOS3NOS1NOS2CCR1CCR5
SCHEMBL24619662 0.74 CCR1 (0.41) CCR1CCR5CCR8CYP2A6CYP1A2
SCHEMBL15077050 0.74 AR (0.40) CCR1CCR5CCR8PDE10ATDP1
SCHEMBL20049057 0.72 NOS3 (0.37) NOS3NOS1NOS2CYP1A2
SCHEMBL4585312 0.71 CCR1 (0.43) NOS3NOS1NOS2CCR1CCR5
SCHEMBL12190549 0.69 PDE2A (0.40) NOS3NOS1NOS2PDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-22 US disclosed
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof GPBAR1, SLC10A1, NR1H4 NOS3 1811/4885NOS1 2806/4885NOS2 2315/4885
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF GPBAR1, SLC10A1, NR1H4 NOS3 1811/4885NOS1 2806/4885NOS2 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.